Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function

Molecular Carcinogenesis

Volumn 52, Issue 7, 2013, Pages 535-543

  Li, Yanli ^a,b   Gong, Yi ^b   Li, Linglin ^b   Abdolmaleky, Hamid M ^b   Zhou, Jin Rong ^a,b  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Apoptosis; Aurora A; Lung cancer; Proliferation; Tanshinones

Indexed keywords

AURORA A KINASE; CRYPTOTANSHINONE; SMALL INTERFERING RNA; TANSHINONE I; TANSHINONE IIA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHINESE HERB; CLONOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; FOOD INTAKE; GENE FUNCTION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALVIA MILTIORRHIZA; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; BODY WEIGHT; CARCINOMA, LEWIS LUNG; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; DITERPENES, ABIETANE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

SALVIA MILTIORRHIZA;

EID: 84879463275     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21888     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43- 66.
2. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005; 172: 523- 529.
3. Eisenberg DM, Davis RB, Ettner SL. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 1998; 280: 1569- 1575.
4. Kumar NB, Allen K, Bell H. Perioperative herbal supplement use in cancer patients: Potential implications and recommendations for presurgical screening. Cancer Control 2005; 12: 149- 157.
5. Zhou L, Zuo Z, Chow MS. Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2005; 45: 1345- 1359.
6. Lee WY, Chiu LC, Yeung JH. Cytotoxicity of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on HepG2 cells in relation to glutathione perturbation. Food Chem Toxicol 2008; 46: 328- 338.
7. Chen W, Luo Y, Liu L, et al. Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin d1 expression and rb phosphorylation. Cancer Prev Res (Phila) 2010; 3: 1015- 1025.
8. Mosaddik MA. In vitro cytotoxicity of tanshinones isolated from Salvia miltiorrhiza Bunge against P388 lymphocytic leukemia cells. Phytomedicine 2003; 10: 682- 685.
9. Song Y, Yuan SL, Yang YM, Wang XJ, Huang GQ. Alteration of activities of telomerase in tanshinone IIA inducing apoptosis of the leukemia cells. Zhongguo Zhong Yao Za Zhi 2005; 30: 207- 211.
10. Sung HJ, Choi SM, Yoon Y, An KS, Tanshinone IIA. an ingredient of Salvia miltiorrhiza BUNGE, induces apoptosis in human leukemia cell lines through the activation of caspase-3. Exp Mol Med 1999; 31: 174- 178.
11. Yoon Y, Kim YO, Jeon WK, Park HJ, Sung HJ. Tanshinone IIA isolated from Salvia miltiorrhiza BUNGE induced apoptosis in HL60 human premyelocytic leukemia cell line. J Ethnopharmacol 1999; 68: 121- 127.
12. Lee CY, Sher HF, Chen HW, et al. Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol Cancer Ther 2008; 7: 3527- 3538.
13. Nizamutdinova IT, Lee GW, Son KH, et al. Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. Int J Oncol 2008; 33: 485- 491.
14. Wang X, Wei Y, Yuan S, et al. Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer 2005; 116: 799- 807.
15. Su CC, Lin YH. Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios. Int J Mol Med 2008; 22: 357- 361.
16. Yuan S, Wang Y, Chen X, Song Y, Yang Y. [A study on apoptosis of nasopharyngeal carcinoma cell line induced by Tanshinone II A and its molecular mechanism]. Hua Xi Yi Ke Da Xue Xue Bao 2002; 33: 84- 86, 90.
17. Wang J, Wang X, Jiang S, et al. Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. J Neurooncol 2007; 82: 11- 21.
18. Liu JJ, Zhang Y, Lin DJ, Xiao RZ. Tanshinone IIA inhibits leukemia THP-1 cell growth by induction of apoptosis. Oncol Rep 2009; 21: 1075- 1081.
19. Yuan SL, Wei YQ, Wang XJ, Xiao F, Li SF, Zhang J. Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells. World J Gastroenterol 2004; 10: 2024- 2028.
20. Wang X, Yuan S, Huang R, Song Y. An observation of the effect of tanshinone on cancer cell proliferation by Brdu and PCNA labeling. Hua Xi Yi Ke Da Xue Xue Bao 1996; 27: 388- 391.
21. Zhang P, Pei Y. Qi Y. Influence of blood-activating drugs on adhesion and invasion of cells in lung cancer patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 1999; 19: 103- 105.
22. Wang X, Yuan S, Wang C. A preliminary study of the anti-cancer effect of tanshinone on hepatic carcinoma and its mechanism of action in mice. Zhonghua Zhong Liu Za Zhi 1996; 18: 412- 414.
23. Gong Y, Li Y, Lu Y, et al. Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice. Int J Cancer 2011; 129: 1042- 1052.
24. Singh AV, Franke AA, Blackburn GL, Zhou JR. Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res 2006; 66: 1851- 1858.
25. Zhou J-R, Mukherjee P, Gugger ET, Tanaka T, Blackburn GL, Clinton SK. The inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res 1998; 58: 5231- 5238.
26. Lentini L, Amato A, Schillaci T, Insalaco L, Di Leonardo A. Aurora-A transcriptional silencing and vincristine treatment show a synergistic effect in human tumor cells. Oncol Res 2008; 17: 115- 125.
27. National Research Council. Guide for the Care and Use of Laboratory Animals. Publish no 85-23 (rev) 1985; NIH: Washington, DC.
28. Mai Z, Blackburn GL, Zhou JR. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Mol Carcinog 2007; 46: 534- 542.
29. Perez de Castro I, de Carcer G, Montoya G, Malumbres M. Emerging cancer therapeutic opportunities by inhibiting mitotic kinases. Curr Opin Pharmacol 2008; 8: 375- 383.
30. Hannak E, Kirkham M, Hyman AA, Oegema K. Aurora-A kinase is required for centrosome maturation in Caenorhabditis elegans. J Cell Biol 2001; 155: 1109- 1116.
31. Marumoto T, Zhang D, Saya H. Aurora-A-A guardian of poles. Nat Rev Cancer 2005; 5: 42- 50.
32. Hirota T, Kunitoku N, Sasayama T, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003; 114: 585- 598.
33. Kaestner P, Stolz A, Bastians H. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther 2009; 8: 2046- 2056.
34. Comperat E, Bieche I, Dargere D, et al. Gene expression study of Aurora-A reveals implication during bladder carcinogenesis and increasing values in invasive urothelial cancer. Urology 2008; 72: 873- 877.
35. Lee EC, Frolov A, Li R, Ayala G, Greenberg NM. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 2006; 66: 4996- 5002.
36. Matarasso N, Bar-Shira A, Rozovski U, Rosner S, Orr-Urtreger A. Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate. Neoplasia 2007; 9: 707- 715.
37. Kumano M, Miyake H, Terakawa T, Furukawa J, Fujisawa M. Suppressed tumour growth and enhanced chemosensitivity by RNA interference targeting Aurora-A in the PC3 human prostate cancer model. BJU Int 2010; 106: 121- 127.
38. Addepalli MK, Ray KB, Kumar B, Ramnath RL, Chile S, Rao H. RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. Gene Ther 2010; 17: 352- 359.
39. Li Y, Zhang ZF, Chen J, et al. VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res 2010; 2: 296- 308.
40. Wang X, Dong L, Xie J, Tong T, Zhan Q. Stable knockdown of Aurora-A by vector-based RNA interference in human esophageal squamous cell carcinoma cell line inhibits tumor cell proliferation, invasion and enhances apoptosis. Cancer Biol Ther 2009; 8: 1852- 1859.
41. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262- 267.
42. Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors-Rising stars in cancer therapeutics? Mol Cancer Ther 2010; 9: 268- 278.
43. Gorgun G, Calabrese E, Hideshima T, et al. A novel aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell cycle arrest in multiple myeloma. Blood 2010; 115: 5202- 5213.
44. Israels LG, Israels ED. Apoptosis. The Oncologist 1999; 4: 332- 339.
45. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27- 31.
46. Cao Y. Angiogenesis: What can it offer for future medicine? Exp Cell Res 2010; 316: 1304- 1308.